Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05909618
Title Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases (14)
Acronym 14
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sheba Medical Center
Indications
Therapies
Age Groups: adult | senior
Covered Countries


No variant requirements are available.